Llwytho...
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki‐67 Is ≥10%?
BACKGROUND: Long‐acting somatostatin analogs (SSAs) are the primary first‐line treatment of well‐differentiated advanced gastroenteropancreatic neuroendocrine tumors (NETs), but data about their efficacy in pancreatic NETs (panNETs) with Ki‐67 ≥10% are still limited. MATERIALS AND METHODS: To assess...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Oncologist |
|---|---|
| Prif Awduron: | , , , , , , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
John Wiley & Sons, Inc.
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8018333/ https://ncbi.nlm.nih.gov/pubmed/33301235 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13633 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|